Relevant bibliographies by topics / Reins – Cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Reins – Cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Reins – Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Reins – Cancer"

1

Mallick, Bibekanand, Jayprokas Chakrabarti, and Zhumur Ghosh. "MicroRNA reins in embryonic and cancer stem cells." RNA Biology 8, no. 3 (2011): 415–26. http://dx.doi.org/10.4161/rna.8.3.14497.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yousef, George, and Eleftherios Diamandis. "Tissue kallikreins: new players in normal and abnormal cell growth?" Thrombosis and Haemostasis 90, no. 07 (2003): 7–16. http://dx.doi.org/10.1055/s-0037-1613593.

Full text
Abstract:
SummarySerine proteases are proteolytic enzymes with an active serine residue in their catalytic site. Kallikreins are a subgroup of the serine protease family and are known to have diverse physiological functions. The human tissue kallikrein gene family has now been fully characterized and includes 15 members, clustered in a 300 kb region on chromosome 19q13.4. In this review, we discuss the common structural features of kallik-reins at the DNA, mRNA and protein levels. Kallikreins are secreted as inactive zymogens and are activated by cleavage of an N-terminal peptide. Some kallikreins can undergo autoactivation while others may be activated by other kallikreins or other proteases. Most kallikreins are predicted to have trypsin-like enzymatic activity except for three members which may have chymotrypsin-like activity. Circumstantial evidence suggests that at least some kallikreins may be part of an enzymatic cascade pathway which is activated in aggressive forms of ovarian and probably other cancers. Accumulating evidence suggests potential diagnostic and/or prognostic roles of kallikreins in diverse malignancies. In addition to PSA, many other kallik-reins show differential expression in malignancy. For example, hK6, 10 and 11 are promising serological markers for ovarian cancer diagnosis. KLK10 may act as a tumor suppressor. In addition to their diagnostic and prognostic values, kallikreins may also be good therapeutic targets.Part of this paper was originally presented at the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September, 2002.
APA, Harvard, Vancouver, ISO, and other styles
3

Fenoglietto, P., S. Vieillot, C. Llacer Moscardo, J. B. Dubois, and D. Azria. "Préservation des deux reins dans le cas de traitements de cancer abdominaux avec RapidArc®." Cancer/Radiothérapie 15, no. 6-7 (2011): 598–99. http://dx.doi.org/10.1016/j.canrad.2011.07.110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wolters, Pamela L., Ana-Maria Vranceanu, Heather L. Thompson, et al. "Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials." Neurology 97, no. 7 Supplement 1 (2021): S50—S63. http://dx.doi.org/10.1212/wnl.0000000000012421.

Full text
Abstract:
ObjectiveTo review and recommend patient-reported outcome (PRO) measures assessing multidimensional domains of quality of life (QoL) to use as clinical endpoints in medical and psychosocial trials for children and adults with neurofibromatosis (NF) type 1, NF2, and schwannomatosis.MethodsThe PRO working group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration used systematic methods to review, rate, and recommend existing self-report and parent-report PRO measures of generic and disease-specific QoL for NF clinical trials. Recommendations were based on 4 main criteria: patient characteristics, item content, psychometric properties, and feasibility.ResultsThe highest-rated generic measures were (1) the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales for NF clinical trials for children or for children through adults, (2) the Functional Assessment of Cancer Therapy–General for adult medical trials, and (3) the World Health Organization Quality of Life–BREF for adult psychosocial trials. The highest-rated disease-specific measures were (1) the PedsQL NF1 Module for NF1 trials, (2) the NF2 Impact on Quality of Life Scale for NF2 trials, and (3) the Penn Acoustic Neuroma Quality of Life Scale for NF2 trials targeting vestibular schwannomas. To date, there are no disease-specific tools assessing multidimensional domains of QoL for schwannomatosis.ConclusionsThe REiNS Collaboration currently recommends these generic and disease-specific PRO measures to assess multidimensional domains of QoL for NF clinical trials. Additional research is needed to further evaluate the use of these measures in both medical and psychosocial trials.
APA, Harvard, Vancouver, ISO, and other styles
5

Clayton, H. M., B. Smith, and A. Egenvall. "Rein tension in novice riders when riding a horse simulator." Comparative Exercise Physiology 13, no. 4 (2017): 237–42. http://dx.doi.org/10.3920/cep170010.

Full text
Abstract:
This study reports tension in the left and right reins when riding a horse simulator that moved only in the sagittal plane. The objective was to determine whether asymmetries in rein tension of novice riders at the rising trot, canter, and halt were present, and if so, to investigate their relationship with the rider’s handedness. The experimental hypothesis was that rein tension would be higher on the side of the rider’s non-dominant hand. 22 novice riders (19 right-handed; 3 left-handed) rode a horse simulator at halt, rising trot and canter. Rein tension was recorded in both reins at a sampling rate of 1000 Hz for 8 s at each gait. The variables measured in rising trot and canter were minimal and maximal tension, the change between minimal and maximal values and mean tension per step at rising trot or per stride at canter. At halt only mean tension during the 8 s recording was measured. Comparisons between right and left reins and between right-handed and left-handed riders were made using mixed models. The results showed no asymmetries in mean tension at halt. In rising trot and canter all significant differences involved higher tension in the right rein regardless of handedness of the riders. During rising trot the minimum was higher in the right rein over all riders and both the mean and maximal values were higher in the right rein in left-handed riders. In canter left-handed riders had higher mean tension in the right rein. All recorded asymmetries had higher tension in the right rein compared with the left and they were more prevalent in left-handed riders which implies higher tension in the non-dominant hand. Rein tension patterns were not symmetrical on the left and right sides and asymmetries in left-handed riders were not mirrored in right-handed riders.
APA, Harvard, Vancouver, ISO, and other styles
6

Clayton, Hilary M., Wesley H. Singleton, Joel L. Lanovaz, and Gary L. Cloud. "Strain gauge measurement of rein tension during riding: a pilot study." Equine and Comparative Exercise Physiology 2, no. 3 (2005): 203–5. http://dx.doi.org/10.1079/ecp200553.

Full text
Abstract:
AbstractA pilot study was performed using a strain gauge transducer intercalated between the bit and the left rein to measure rein tension dynamically during riding. The strain patterns consisted of a series of spikes with frequencies corresponding to two per stride in walk and trot and one per stride in canter. The highest tension recorded in each gait was 43 N at walk, 51 N at trot and 104 N in canter. Based on the results of this study, it is recommended that the methodology should be adapted so that both reins are instrumented simultaneously, data are transmitted telemetrically to eliminate the need for a tether connecting the horse to the computer, and kinematic data are synchronized with the rein tension recordings.
APA, Harvard, Vancouver, ISO, and other styles
7

Piccolo, Lara, and Kathrin Kienapfel. "Voluntary Rein Tension in Horses When Moving Unridden in a Dressage Frame Compared with Ridden Tests of the Same Horses—A Pilot Study." Animals 9, no. 6 (2019): 321. http://dx.doi.org/10.3390/ani9060321.

Full text
Abstract:
Too much rein tension while riding may compromise the welfare of the horse. But who generates the tension on the reins—the horse or the rider? The primary aim of this pilot study was to evaluate the maximum rein tension that horses voluntarily maintain without a rider compared to rein tension with a rider. A secondary aim was to evaluate conflict behaviours in relation to rein tension. Thirteen horses were used, all fitted with customised “Animon” rein tension sensors (25 Hz, up to 600 N range), free-moving with side reins set in dressage competition frame with the noseline on the vertical. Rein tension was measured at the walk, trot, and canter in both directions in a round pen. The same horses were then ridden by their usual riders and completed the same task on a riding ground. Continuous video recordings were obtained to subsequently quantify the occurrence of conflict behaviours. The difference in mean maximum peak of rein tension with and without a rider for each gait was compared using the Wilcoxon Rank Sum test. Without a rider, rein tension was significantly lower (Wilcoxon T = 0, p < 0.01, 7.5 N ± 2.8 N) than with a rider (Wilcoxon T = 0, p < 0.01, 24.0 N ± 12.3 N). Regardless of the different rein tensions in the ridden exercise, all of the horses exhibited approximately the same amount of rein tension in the unridden exercise. The frequency of conflict behaviour was higher with a rider than without (11 ± 14 per minute vs. 2 ± 3 per minute; T = 4, p < 0.01).
APA, Harvard, Vancouver, ISO, and other styles
8

Egenvall, A., M. Eisersiö, M. Rhodin, R. van Weeren, and L. Roepstorff. "Rein tension during canter." Comparative Exercise Physiology 11, no. 2 (2015): 107–17. http://dx.doi.org/10.3920/cep150005.

Full text
Abstract:
Riders generally use reins as a means for communication with the horse. At present, the signalling pattern is poorly understood. The aim of this study was to illustrate and analyse the rein tension patterns in a number of rider/horse combinations across a variety of exercises in the canter gait. Our hypothesis was that some riders will follow the movement of the horse more closely than others. Data were collected from eight professional riders riding each three (in one case two) horses that were familiar to them in canter. Horses were instrumented with rein tension meters logged by inertial measurement unit technique (IMU). Inside and outside rein tension data were synchronised with the gait using the vertical acceleration IMU-signal at the poll. Stride-split data (0-100 percentages) were analysed using mixed models technique to elucidate the inside/outside and stride percentage interaction, taking into account the exercises performed. In general, tension was maximal just before the beginning of vertical stance, as defined by the maximal acceleration of the head, with the release closer to the suspension phase. The release was significantly more marked on the outside rein, but between riders and horses the pattern varied substantially. In total 26% of the variation was represented by riders and 21% by the horses. On average there were significant inside/outside rein differences, but at the same time in some horse/rider combinations these differences did not exist.
APA, Harvard, Vancouver, ISO, and other styles
9

Kachuri, L., P. De, LF Ellison, and R. Semenciw. "Tendances concernant l'incidence du cancer, la mortalité par cancer et la survie au cancer au Canada entre 1970 et 2007." Maladies chroniques et blessures au Canada 33, no. 2 (2013): 80–92. http://dx.doi.org/10.24095/hpcdp.33.2.03f.

Full text
Abstract:
Introduction La surveillance des tendances concernant le cancer peut aider à évaluer les progrès réalisés dans la lutte contre le cancer ainsi qu'à renforcer les activités de prévention. La présente étude, fondée sur les données des bases de données nationales, consiste en un examen des tendances à long terme relatives à certains cancers au Canada. Méthodologie Nous avons examiné les changements annuels dans les tendances relatives aux taux d'incidence et de mortalité normalisés selon l'âge observés entre 1970 et 2007 selon le sexe pour tous les cancers combinés, pour les quatre cancers les plus courants (cancer de la prostate, cancer du sein, cancer du poumon, cancer colorectal) et pour les cancers dont les tendances ont été marquées par les changements les plus importants au cours des dernières années. Le rapport de survie relative à cinq ans pour les années 1992 à 2007 a également été calculé. Résultats Pendant la période visée par l'étude, les taux d'incidence de l'ensemble des cas de cancer primitif combinés ont augmenté de 0,9 % par année chez les hommes et de 0,8 % par année chez les femmes. Les taux concernant le mélanome, le cancer de la thyroïde, le cancer du foie, le cancer de la prostate, le cancer du rein, le cancer colorectal, le cancer du poumon, le cancer du sein et le cancer de la vessie ont augmenté à des rythmes variables, et les taux concernant le cancer du larynx, le cancer de la bouche, le cancer de l'estomac et le cancer du col de l'utérus ont diminué. Pour l'ensemble des cancers combinés et pour la plupart des cancers examinés, à l'exception du mélanome et du cancer du poumon chez les femmes, les taux de mortalité ont diminué significativement. Les taux de survie qui ont le plus augmenté sont ceux du cancer de la prostate, du cancer du foie, du cancer colorectal et du cancer du rein. Bien que les tendances globales concernant les taux de mortalité et la survie indiquent que des progrès notables ont été réalisés dans la lutte contre le cancer, la tendance à la hausse des taux d'incidence de certains cancers soulignent la nécessité de poursuivre les efforts dans le domaine de la prévention.
APA, Harvard, Vancouver, ISO, and other styles
10

Zakaria, Dianne, and Amanda Shaw. "Cancers attribuables à l’excès de poids au Canada en 2010." Promotion de la santé et prévention des maladies chroniques au Canada 37, no. 7 (2017): 223–34. http://dx.doi.org/10.24095/hpcdp.37.7.01f.

Full text
Abstract:
Introduction L’excès de poids (indice de masse corporelle [IMC] de 25,00 kg/m2 ou plus) est un facteur de risque bien connu de diabète, d’hypertension et de maladie cardiovasculaire, mais on en sait moins sur son lien avec le cancer. Dans cette étude, nous avons utilisé le risque attribuable dans la population (RAP) pour estimer le fardeau des cancers attribuables à l’excès de poids chez les adultes canadiens (de 25 ans ou plus) en 2010. Méthodologie Nous avons estimé les RAP en utilisant des estimations du risque relatif (RR) tirées du Continuous Update Project du World Cancer Research Fund International, des estimations du surpoids et de l’obésité fondées sur l’IMC tirées de l’Enquête sur la santé dans les collectivités canadiennes de 2000-2001 (surpoids : 25,00 à 29,99 kg/m2; obésité : 30,00 kg/m2 et plus) et nous avons utilisé les nombres de cas de cancer figurant dans le Registre canadien du cancer. Les RAP ont été fondés sur des IMC corrigés pour tenir compte du biais associé à l’autodéclaration de la taille et du poids. Résultats Au Canada, en 2010, on peut attribuer environ 9 645 cas de cancer à un excès de poids, ce qui représente 5,7 % de tous les cas de cancer (hommes : 4,9 %; femmes : 6,5 %). En limitant l’analyse aux types de cancer associés à un IMC élevé, le RAP augmente à 14,9 % (hommes : 17,5 %; femmes : 13,3 %). Les types de cancer pour lesquels le RAP était le plus élevé étaient l’adénocarcinome de l’oesophage (42,2 %), le cancer du rein (25,4 %), le cancer du cardia (20,7 %), le cancer du foie (20,5 %), le cancer du côlon (20,5 %) et le cancer de la vésicule biliaire (20,2 %) chez les hommes, et l’adénocarcinome de l’oesophage (36,1 %), le cancer de l’utérus (35,2 %), le cancer de la vésicule biliaire (23,7 %) et le cancer du rein (23,0 %) chez les femmes. Les types de cancer pour lesquels le nombre de cas attribuables était le plus élevé étaient le cancer du côlon (1 445), le cancer du rein (780) et le cancer de la prostate à un stade avancé (515) chez les hommes, et le cancer de l’utérus (1 825), le cancer du sein postménopausique (1 765) et le cancer du côlon (675) chez les femmes. Quels que soient le sexe et le type de cancer, les RAP étaient les plus élevés dans les Prairies (sauf en Alberta) et la région de l’Atlantique, et les plus faibles en Colombie-Britannique et au Québec. Conclusion Le fardeau du cancer attribuable à l’excès de poids est considérable et continuera de croître à court terme en raison de la hausse de la prévalence du surpoids et de l’obésité au Canada.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Reins – Cancer"

1

Ayari, Cherifa. "Optimisation de l'immunothérapie non spécifique du cancer superficiel de la vessie." Doctoral thesis, Université Laval, 2012. http://hdl.handle.net/20.500.11794/23499.

Full text
Abstract:
Le cancer superficiel de la vessie (CSV) présente un taux élevé de récidive (60%). De ces récidives 10 à 15% progresseront vers un cancer infiltrant beaucoup plus dangereux. La résection transurétrale (RTU) des tumeurs superficielles est souvent suivie d’immunothérapie intravésicale par le BCG (Bacille-Calmette-Guérin) afin de prévenir la récidive et la progression ; cependant ce traitement échoue dans 40% des cas. De plus, la sévérité des effets secondaires empêche plusieurs patients de tolérer un traitement complet. La prédiction de la réponse au BCG et le développement de traitements alternatifs s’avèrent donc nécessaires. Nous avons d’abord évalué la signification clinique de la présence de cellules dendritiques matures infiltrant la tumeur (CDIT) et de macrophages associés aux tumeurs (MAT) dans des CSV à bas risque, traités seulement par RTU. La présence de CDIT a permis d’identifier des patients à risque élevé de progression. Chez des patients à haut risque de récidive et de progression traités au BCG, nous avons observé que ceux qui ont un haut niveau d'infiltration par des CDIT ou des MAT ne répondaient pas efficacement au BCG. Dans un deuxième volet, j’ai exploré la possibilité d’utiliser d’autres agents théarapeutiques pouvant se combiner au BCG ou le remplacer pour stimuler la réponse antitumorale. Pour un tel rôle j’ai choisi les agonistes des Toll-like receptors (TLR). Les TLR, principalement exprimés par les cellules du système immunitaire et quelques cellules épithéliales, jouent un rôle important dans l’immunité innée en reconnaissant des motifs moléculaires conservés de pathogènes. J’ai d’abord montré que les TLR sont exprimés et fonctionnels dans des cellules urothéliales normales et tumorales. Par la suite, j’ai démontré que le poly(I :C), agoniste du TLR3, a un effet cytotoxique et antiprolifératif direct sur des lignées de cancer de vessie. Dans les cellules MGH-U3, il induit également la sécrétion de cytokines pro-inflammatoires et induit fortement l’expression des molécules du CMH de classe I alors que le BCG a très peu d’effet sur l’immunogénicité de ces cellules. Un essai d’inhibition de croissance tumorale utilisant le modèle de cancer de vessie murin MBT-2 a montré que l’utilisation combinée du BCG et du poly(I :C) inhibe très significativement la croissance tumorale alors que chacun des produits utilisés seuls n’avait pas d’effet significatif. Notre étude suggère que le poly(I :C) dû à ses effets anti-néoplasiques pourrait améliorer l’efficacité thérapeutique du BCG dans l’immunothérapie du CSV.<br>Non-muscle invasive bladder cancer (NMIBC) is characterized by a high rate of recurrence (60%). Ten to fiftheen % of the recurrences will progress toward muscle-invasive tumors, which are more dangerous. Transurethral resection (TUR) of non-muscle invasive tumors is frequently followed by intravesical immunotherapy using BCG (bacillus Calmette-Guérin) to prevent recurrence and progression but this treatment fails in 40% of cases. Moreover, the severity of the side effects prevents many patients to comply with the whole treatment. Tools to predict the response to BCG and the development of alternative treatments are therefore required. We first evaluated the clinical significance of the presence of tumor infiltrating mature dendritic cells (TIDCs) and of tumor-associated macrophages (TAMs) in low-risk NMIBCs treated only by TUR. The presence of TIDCs allowed the identification of patients that were at high risk of progression. In patients with NMIBCs at high risk of recurrence and progression treated with BCG, we observed that those with a high level of MAT or TIDC infiltration did not respond efficiently to BCG. In the second part of my work, I have explored the possibility to use other immunomodulatory agents to replace or complement BCG immunotherapy. I therefore selected toll-like receptors (TLRs) agonists for this purpose. TLRs, which are mainly expressed in immune cells but also epithelial cells, play an important role in the innate immunity by recognizing molecular patterns that are conserved between pathogens. I have first showed that TLRs are expressed and functional in normal and tumor urothelial cells. Then, I showed that poly(I:C), a TLR3 agonsist, has direct cytotoxic and antiproliferative effects on bladder cancer cell lines. In MGH-U3 cells, it induces the secretion of proinflammatory cytokines and expression of major histocompatibility class I molecules whereas BCG has little effect on the immunogenicity of these cells. A growth inhibition assay using the MBT-2 murine bladder cancer model showed that the combination of poly(I:C) and BCG inhibited very significantly the growth of bladder cancer cells whereas each product alone had no significant effect. Our study suggests that poly(I:C), due to its anti-tumoral effects, could improve the therapeutic efficacy of BCG for the immunotherapy of NMIBCs.
APA, Harvard, Vancouver, ISO, and other styles
2

LOUIS, BRUNO. "Toux et cancer du rein." Dijon, 1994. http://www.theses.fr/1994DIJOM071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Desfour, Hugues. "Le cancer du rein vu en milieu rhumatologique." Montpellier 1, 1989. http://www.theses.fr/1989MON11055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Puech, Albert. "L'adénocarcinome rénal de l'enfant, à propos d'un cas : revue de la littérature." Montpellier 1, 1992. http://www.theses.fr/1992MON11233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

ALBARIDI, ADNAN. "Pronostic du cancer du rein de l'adulte : a propos de 312 observations." Saint-Etienne, 1991. http://www.theses.fr/1991STET6212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

LEVIGNE, FREDERIC. "Le cancer du rein de l'adulte : a propos de 230 observations." Saint-Etienne, 1989. http://www.theses.fr/1989STET6009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hostyn, Bruno. "La place de la chirurgie conservatrice dans le cancer du rein : discussion à propos de 42 observations et revue de la littérature." Bordeaux 2, 1994. http://www.theses.fr/1994BOR23079.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lanoux, Patricia. "Syndrome de Cushing et cancer du rein : à propos d'une observation." Reims, 1989. http://www.theses.fr/1989REIMM119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dumond, Aurore. "Les Neuropilines, des cibles pertinentes dans le traitement du cancer du rein à cellules claires." Electronic Thesis or Diss., Université Côte d'Azur, 2020. http://www.theses.fr/2020COAZ6033.

Full text
Abstract:
Les cancers du rein à cellules claires (ccRCC) représentent 80% des cancers du rein. Environ 80% des ccRCC présentent une inactivation/ mutation du gène de Von Hippel-Lindau (VHL), entraînant la stabilisation des facteurs inductibles d'hypoxie 1 et 2 alpha (HIF1 et 2α) et la surexpression de leurs gènes cibles tels que "le facteur de croissance vasculaire endothélial (VEGF)", le principal facteur d'angiogenèse. Ainsi les ccRCC sont les cancers les plus vascularisés et représentent un paradigme pour les traitements anti-angiogéniques (AAT). Aujourd'hui, 15 différents AAT ont obtenu l'approbation de la FDA et de l'EMA. Ils sont divisés en trois familles :- les anticorps ciblant les VEGFs- les inhibiteurs de tyrosine-kinase (TKi), qui ciblent les récepteurs impliqués dans la néo-angiogenèse, tel que le sunitinib- les récepteurs « leurres » qui piègent le VEGFA et le PlGF tel que l’aflibercept.La surexpression du VEGF (impliqué dans l'angiogenèse), et des autres membres de la famille du VEGF, le VEGFC (impliqué dans la lymphangiogenèse) est un phénomène clé dans la tolérance immune. Ainsi, des inhibiteurs de points de contrôle immunitaire (anti PD-1, anti PD-L1 et anti CTLA-4) ont aussi obtenu l'approbation des autorités de santé pour le traitement des ccRCC.En revanche, une rechute après quelques mois de traitement par les TKi est souvent observée et les inhibiteurs de points de contrôle immunitaire présentent une efficacité sur seulement 20% des patients. Ainsi, le ccRCC reste incurable chez une majorité de patients et de nouvelles stratégies thérapeutiques ciblant à la fois l'angiogenèse, la lymphangiogenèse et la tolérance immune sont nécessaires.Les Neuropilines (NRP1 et NRP2) sont des corécepteurs de VEGF et de VEGFC et sont exprimés sur les cellules endothéliales vasculaires et lymphatiques, sur les cellules tumorales et sur les cellules du système immunitaire. Ainsi, les Neuropilines sont de nouvelles cibles pertinentes pour le traitement du ccRCC.Ma thèse décrit la pertinence du ciblage des voies de signalisation NRP1 et NRP2 dans les ccRCC par une approche génétique (invalidation des deux gènes par CRISPR/Cas9) et par une approche pharmacologique (développement d’un inhibiteur des NRPs). Les résultats précliniques générés représentent une première étape essentielle pour l’initiation d’essais cliniques de phase précoce pour les patients en échec thérapeutique<br>Clear cell Renal Cell Carcinoma (ccRCC) represent 80% of kidney cancers. Around 80% of ccRCC present an inactivation of the von Hippel-Lindau gene (VHL) gene, leading to the stabilization the Hypoxia Inducible Factors 1 and 2 alpha (HIF-1 and 2α) and to the overexpression of their targeted genes such as the « Vascular Endothelial Growth Factor (VEGF) », the principal angiogenic factor. Thus, ccRCC are one of the most vascularized cancers and represent a paradigm for anti-angiogenic treatments (AAT). Currently,15 different AAT have obtained FDA and EMA approval. They are divided in three different families:- antibodies targeting VEGF- tyrosine-kinase inhibitors (TKi) that target receptors involved in neo-angiogenesis such as the current reference therapy, sunitinib- decoy receptors that trap VEGFA and PlGF such as aflibercept.Overexpression of VEGF (involved in angiogenesis) and of the other member of the VEGF family, VEGFC (involved in lymphangiogenesis) is also a key phenomenon of immune tolerance. Therefore, immune-checkpoint inhibitors (anti PD-1, anti PD-L1 and anti CTLA-4) also obtained an approval for the treatment of ccRCC.However, relapse on TKi are frequently observed after a few months and immune-checkpoint inhibitors present a long-lasting effect only in 20% of patients. Hence, ccRCC is still an uncurable disease and new therapeutic strategies targeting concomitantly angiogenesis/lymphangiogenesis and immune tolerance are urgently needed. Neuropilins (NRP1 and NRP2) are co-receptors of VEGF and VEGFC and are expressed on vascular and lymphatic endothelial cells, on tumor cells and on immune cells. Hence, they may represent ideal targets to inhibit the drivers of ccRCC aggressiveness.My thesis describes the relevance of targeting the NRP1 and NRP2 signaling pathways in ccRCC by a genetic (invalidation of the two genes by CRISPR/Cas9) and by a pharmacological approach (development of a NRPs inhibitor). The preclinical results generated represent an essential first step for the initiation of early phase clinical trials for patients with treatment failure
APA, Harvard, Vancouver, ISO, and other styles
10

Chomy, Isabelle. "Métastases rénales de tumeurs solides : à propos de trois cas de cancers broncho-pulmonaires : revue de la littérature." Bordeaux 2, 1989. http://www.theses.fr/1989BOR25227.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Reins – Cancer"

1

Edson, Pontes J., and Bukowski Ronald M, eds. Clinical management of renal cell cancer. Year Book Medical Publishers, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stephane, Oudard, ed. Le cancer du rein. Ellipses, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Primary cancer (encephaloid) of the kidney during childhood. W. Wood, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Primary cancer (encephaloid) of the kidney during childhood. W. Wood, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Le Cancer du rein. Springer Paris, 2008. http://dx.doi.org/10.1007/978-2-287-71651-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Benoît, Gérard. Le cancer du rein de l'adulte. John Libbey Eurotext, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

(Editor), Stéphane Culine, and Jean-Jacques Patard (Editor), eds. Le Cancer du rein (Oncologie pratique). Springer, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rein, R. Rein Molecular Basis of Cancer - Macromolecular Recognition Chemotherapy & Immunology. John Wiley & Sons Inc, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rein, R. Rein Molecular Basis of Cancer - Macromolecular Structure Carcinogens & Oncogenes. John Wiley & Sons Inc, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kidney Cancer: Recent Results of Basic and Clinical Research (Contributions to Nephrology). S. Karger AG (Switzerland), 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Reins – Cancer"

1

Pouessel, D., J. J. Patard, and S. Culine. "Cancer du rein." In Thérapeutique du cancer. Springer Paris, 2011. http://dx.doi.org/10.1007/978-2-8178-0021-9_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Grosclaude, P., and M. Velten. "Rein." In Survie des patients atteints de cancer en France. Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-39310-5_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rischmann, P., Ph Courriere, J. P. Sarramon, and N. Bouhacina. "Recepteurs Hormoneux Steroidiens et Cancer du Rein — Correlations Anatomocliniques." In 40. Tagung, 28. September–1. Oktober 1988, Saarbrücken. Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83800-2_327.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Coulange, C., A. Elias, H. Leremboure, et al. "Recherche de l’Envahissement Veineux dans le Cancer du Rein-Intérét de l’Echo-Doppler et de I.R.M." In 40. Tagung, 28. September–1. Oktober 1988, Saarbrücken. Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83800-2_164.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jacqmin, D., G. Perrot, M. Weber, et al. "Complications de la Chirurgie de la Veine Cave pour Cancer de Rein-Analyse d’une Série de 47 Cas." In 40. Tagung, 28. September–1. Oktober 1988, Saarbrücken. Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83800-2_165.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Non-Coding RNAs : The New Reins in Malignancies." In Rediscovering Cancer: From Mechanism to Therapy. Apple Academic Press, 2018. http://dx.doi.org/10.1201/9781351166560-25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Alexandre, J., A. Balian, L. Bensoussan, et al. "Cancer du rein." In Le tout en un révisions IFSI. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70633-2.50018-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Cancer du rein." In Méga Guide STAGES IFSI. Elsevier, 2015. http://dx.doi.org/10.1016/b978-2-294-74529-4.00018-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Cancer du rein." In Protocoles de traitement. Service d’hémato-oncologie HDQ-HDL 2020 (9e édition). Presses de l'Université Laval, 2020. http://dx.doi.org/10.2307/j.ctv1h0p3z5.50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Roy, C., P. Barthélémy, and E. Rust. "Aspect post-thérapeutique du cancer du rein." In Imagerie Post-Thérapeutique en Oncologie. Elsevier, 2014. http://dx.doi.org/10.1016/b978-2-294-73840-1.00008-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Reins – Cancer"

1

De Figueiredo, Wenberger Lanza Daniel, Paula Taquita Serra, and Diego Monteiro De Carvalho. "UTILIZAÇÃO DO SISTEMA CRISPR-CAS9 PARA O TRATAMENTO DE CARCINOMA PAPILÍFERO DE TIREOIDE: REVISÃO DE LITERATURA." In I Congresso Brasileiro de Biotecnologia On-line. Revista Multidisciplinar de Educação e Meio Ambiente, 2021. http://dx.doi.org/10.51189/rema/1105.

Full text
Abstract:
Introdução: O CRISPR/Cas9 é um sistema de tratamento para câncer baseado na edição do DNA que pode mudar os tratamentos para carcinoma papilífero de tireoide. Objetivo: Revisar na literatura a utilização do sistema CRISPR-CAS9 nos tratamentos para carcinoma papilífero de tireoide. Material e métodos: Realizou-se uma revisão de literatura combinando os seguintes descritores: “CRISPR-Associated Proteins e Thyroid Cancer, Papillary” nas plataformas PubMed, BVS e SciELO por artigos publicados há 5 anos completos e gratuitos. Por fim, incluiu-se 5 textos, 2 foram analisados por relacionarem-se ao tema do estudo. Resultados: As equipes de pesquisa do Reino Unido e da Grécia realizaram experimentação in vitro e in vivo de amostras retiradas de tecido vivo pós-cirúrgico com triagem por imuno-histoquímica de 170 amostras de tecido tireoidiano. O sistema de CRISPR/Cas9 possibilitou o knockdown de SLC35F2 em células cancerígenas que inibiu significativamente a proliferação, aboliu as habilidades de formação de colônias e atenuou a invasão e metástase de células cancerosas da tireoide. Dessa forma, viabilizou a suspeição do SLC35F2 como um importante preditor de metástases em linfonodos para pacientes com carcinoma de tireoide. Ademais, o knockdown por CRISPR/Cas9 de Ku80 reduziu significativamente a proliferação, invasão e formação de tumor em células tireoidianas. Teve efeitos no aumento significativo da taxa de apoptose, além de regular negativamente as moléculas relacionadas à via de sinalização de MAPK e proteínas associadas à proliferação e metástase das células. Por fim, demonstrou que o Ku80 está envolvido na patogênese do câncer de tireoide. Conclusão: Em suma, a técnica por CRISPR/Cas9 aplicada em cultura de células tumorais de tireoide demonstrou ser útil quanto ao silenciamento de genes envolvidos na metástase e proliferação. Assim, embora seja necessário melhor estudo do tema em humanos, supõe-se que a aplicação clínica futura em pacientes portadores da doença será possível.
APA, Harvard, Vancouver, ISO, and other styles
2

Paizs, Petra, Eftychios Manoli, Sam E. Mason, et al. "Abstract 4536: Rapid evaporative ionization mass spectrometry (REIMS) analysis of the mucosal lipidome has a high diagnostic accuracy for adenomas and early colorectal cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4536.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kinross, James Macalister, Laura Muirhead, James Alexander, et al. "Abstract 3977: iKnife: Rapid evaporative ionization mass spectrometry (REIMS) enables real-time chemical analysis of the mucosal lipidome for diagnostic and prognostic use in colorectal cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3977.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Reins – Cancer' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography